Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma

2017 ◽  
Vol 27 (4) ◽  
pp. 979-985 ◽  
Author(s):  
Nina Shah ◽  
Qiuling Shi ◽  
Sergio Giralt ◽  
Loretta Williams ◽  
Qaiser Bashir ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Functional Impairment ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Patient Reported Outcome ◽  
Cell Transplant ◽  
Patient Reported

scholarly journals Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma

eJHaem ◽  
2021 ◽  
Author(s):  
Noa Biran ◽  
Wanting Zhai ◽  
Roxanne E. Jensen ◽  
Jeanne Mandelblatt ◽  
Susan Kumka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Patient Reported Outcomes ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Patient Reported

Tandem versus single autologous stem cell transplant: A patient-reported outcome.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20026-e20026
Author(s):  
Thomas H. Molina ◽  
Nathan W. Sweeney ◽  
Nolan Cole ◽  
Jenny Ahlstrom
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Progression Free Survival ◽  
Autologous Stem Cell Transplant ◽  
Patient Reported Outcome ◽  
Cell Transplant ◽  
Patient Centered ◽  
Chi Square ◽  
Depth Analysis ◽  
Patient Reported

e20026 Background: Whether tandem autologous stem cell transplant (ASCT) is superior to single ASCT for new diagnosed multiple myeloma (MM) patients remains a subject of discussion in the era of novel agents. This project analyzed patient-reported outcomes to single ASCT and tandem ASCT utilizing an online patient-centered platform. Methods: We analyzed patient-reported treatment outcomes pertaining to tandem ASCT and single ASCT from HealthTree Cure Hub ( www.healthtree.org ). In this study, we examined whether patients reported a reduction or no reduction in their myeloma after their tandem or single ASCT. The association between stem cell transplant and myeloma outcome was compared by chi-squared test. Results: In this retrospective analysis of 945 MM patients, we compared two groups, those that reported receiving a tandem ASCT (n = 75) and those that reported receiving a single ASCT (n = 870). Our analysis revealed an association between patients who reported receiving a tandem ASCT and a reduction of their myeloma (chi-square (1) = 3.87, p = .04), compared to patients who reported receiving a single ASCT. Conclusions: Tandem ASCT was perceived by patients to be superior over single ASCT in regard to myeloma reduction for the HealthTree patient population. A more in-depth analysis of the patient-provided health data from HealthTree could aid in determining factors related to survival as well as help to quickly answer lingering questions related to tandem ASCT, such as timing, genetic factors, progression free survival, and more.[Table: see text]

scholarly journals Patient-Reported Outcomes and Patient-Performed Testing in Measuring Functional Impairment after Stem Cell Transplant in Patients with Multiple Myeloma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 538-538
Author(s):  
Nina Shah ◽  
Sergio A. Giralt ◽  
Qiuling Shi ◽  
Loretta A. Williams ◽  
Qaiser Bashir ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Longitudinal Study ◽  
Functional Status ◽  
Functional Impairment ◽  
Stem Cell Transplant ◽  
Completion Rate ◽  
Walking Distance ◽  
Cell Transplant ◽  
Patient Reported

Abstract Objectives: In cancer patients undergoing intensive therapy such as stem cell transplant, functional recovery is an important but challenging outcome to measure. This prospective, longitudinal study aimed to demonstrate how a patient-reported outcome (PRO) could predict patient-performed testing (PPT) for measuring functional impairment after autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM). Methods: A secondary analysis was conducted using data from a randomized controlled trial of 2 stem cell doses for MM patients undergoing ASCT. Symptom interference on walking (a PRO) was measured by the MD Anderson Symptom Inventory (MDASI), on a 0-10 scale, with a higher score referring to a greater interference. The PPT outcome was assessed via distance walked on the six-minute walk test (6MWT). MDASI and 6MWT were administrated before ASCT, and on days 0, 3, 5, 7, 14, 21 and 28 from ASCT. Mixed effects modeling was used to examine 1) the longitudinal relationship between MDASI-walking symptom interference score and 6MWT walking distance and 2) the MDASI-walking symptom interference scores between patients who completed 6WMT and those who did complete the test. Results: Seventy-nine patients were included in the study. Of note, no significant clinical, functional or symptom differences were detected between the 2 doses of stem cells (Shah et al, BBMT 2015); thus the entire study population was considered in the same cohort. The average pre-ASCT walking distance was 452±185 feet and MDASI-walking score was 2.1±2.6. From day of transplant, the 6MWT decreased until day 5 (329±140, P=0.04, compared to pre-ASCT) and then recovered to pre-ASCT level at day 28 (408±131, p=0.176, compared to pre-ASCT). MDASI-walking interference symptom score worsened until day 7 (4.7±3.2, P<.0001, compared to pre-ASCT level) and returned to pre-ASCT level at day 28 (2.8±2.9, P=0.138). The 6MWT-walking distance significantly correlated with the MDASI-walking interference symptom score over the first month of ASCT (est=-6.09, p=0.006, Figure 1). All patients (79) completed pre-ASCT MDASI and 70 completed 6MWT pre-ASCT. Completion rate for both measures were decreased after ASCT. The lowest completion rate for 6MWT was found on day 7 (38%) and day 14 for MDASI (76%). There was a significantly higher completion rate for the MDASI versus 6MWT at each time point (p<0.01 for all). Patients who completed the 6MWT reported lower MDASI-walking scores (indicating better walking functioning) than those who did not complete 6MWT at day 3 (3.25 vs. 5.09, p=0.033), day 5 (3.09 vs. 5.70, p=0.02), day 7 (3.30 vs. 5.80, p=0.02), and day 14 (3.45 vs. 5.55, p=0.019). The mixed model showed that this difference was significant over the transplant course (est=1.61, p<.0001, Figure 2). Conclusion: PRO-based functioning as measured by an interference item on the MDASI significantly correlates with a functional measure such as the 6MWT in MM patients undergoing ASCT. As patients with poorer functional status during ASCT are more likely to miss the 6MWT, the MDASI or other PRO tools may offer a more practical quantitative measure of functioning in patients with low functional status. This is one of the first studies to demonstrate a link between a PRO and objective physical functional status by a longitudinal study in ASCT. Figure 1. MDASI-walking and 6MWT-walking distance are longitudinally correlated (est=-6.09, p=0.006) Figure 1. MDASI-walking and 6MWT-walking distance are longitudinally correlated (est=-6.09, p=0.006) Figure 2. MDASI-walking scores between patients completing or not completing 6MWT (est=1.61, p<.0001) Figure 2. MDASI-walking scores between patients completing or not completing 6MWT (est=1.61, p<.0001) Disclosures No relevant conflicts of interest to declare.

scholarly journals Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma

2014 ◽  
Vol 56 (5) ◽  
pp. 1335-1341 ◽  
Author(s):  
Xin Shelley Wang ◽  
Qiuling Shi ◽  
Loretta A. Williams ◽  
Nina D. Shah ◽  
Tito R. Mendoza ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Longitudinal Analysis ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Patient Reported

Poster: MM-293: Early Relapse After Autologous Stem Cell Transplant in Multiple Myeloma: Single-Center Experience in Salamanca, Spain

2021 ◽  
Vol 21 ◽  
pp. S254
Author(s):  
Felipe Peña-Muñoz ◽  
Luz Román-Molano ◽  
Danylo Palomino-Mendoza ◽  
Alberto Hernández-Sánchez ◽  
Borja Puertas-Martínez ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Autologous Stem Cell Transplant ◽  
Cell Transplant ◽  
Single Center ◽  
Early Relapse ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document